23 May 2016 14:35
4D pharma plc
(the "Company" or "4D")
Result of AGM
At the annual general meeting of 4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, held earlier today, all resolutions put to shareholders were duly passed.
The full text of each resolution was included in the notice of the meeting, contained in the Company's Annual Report which was posted to shareholders on 22 April 2016 and is available on the Company's website www.4dpharmaplc.com.
For further information please contact:
4D | + 44 (0) 113 895 0130 |
Laurie Dale, Company Secretary
|
|
|
|
Zeus Capital Limited - Nomad and Broker |
|
Dan Bate | +44 (0) 161 831 1512 |
Dominic Wilson | +44 (0) 203 829 5000 |
About 4D
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D currently has a pipeline of 13 preclinical programmes, covering disease areas such as rheumatoid arthritis, multiple sclerosis and cancer, and is currently conducting patient trials in Irritable Bowel Syndrome and Paediatric Crohn's Disease. The programmes in Paediatric Ulcerative Colitis and Paediatric Crohn's Disease have both been granted Orphan Drug Status by the FDA.